<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ETHINYL ESTRADIOL</span><br/>(eth'in-il ess-tra-dye'ole)<br/><span class="topboxtradename">Estinyl, </span><span class="topboxtradename">Feminone<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">estrogen</span><br/><b>Prototype: </b>Estradiol<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.02 mg, 0.05 mg, 0.5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Oral estrogen with actions similar to those of estradiol. Given cyclically for short-term use.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binds to intracellular receptors that stimulate DNA and RNA to synthesize proteins responsible for effects of estrogen.</p>
<h1><a name="uses">Uses</a></h1>
<p>Moderate to severe vasomotor symptoms associated with menopause; also postmenopausal osteoporosis, female hypogonadism, and
         as palliation for inoperable, metastatic cancer of female breast (at least 5 y postmenopause) and of the prostate.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Postcoital contraceptive.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Breast cancer; known or suspected pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; gallbladder disease; diabetes mellitus; heart failure; liver or kidney dysfunction, history of thromboembolic
         disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Menopause, Postmenopausal Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.020.05 mg/d for 21 d each month, adjust to lowest level that gives symptom control<br/><br/><span class="indicationtitle">Female Hypogonadism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.05 mg 13 times/d for 2 wk, followed by 2 wk of progestin, continue this regimen for 36 mo<br/><br/><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1 mg t.i.d. for 23 mo<br/><br/><span class="indicationtitle">Prostatic Cancer Palliation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.152 mg/d<br/><br/><span class="indicationtitle">Postcoital Contraceptive</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg/d for 5 consecutive days beginning within 72 h of coitus<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Morning-after pill: Start drug within 24 h and not later than 72 h after sexual exposure when used as an emergency postcoital
            contraceptive. Perform a pregnancy test prior to dosing.
         </li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, depression, <span class="speceff-common">libido changes.</span> <span class="typehead"> CV:</span> <span class="speceff-life">Thromboembolic disorders</span>, hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> vomiting, diarrhea, anorexia, weight changes, bloating, cholestatic jaundice. <span class="typehead">Urogenital:</span> Mastodynia, breakthrough bleeding, changes in menstrual flow, dysmenorrhea, amenorrhea; in men: impotence, gynecomastia, testicular
      atrophy. <span class="typehead">Metabolic:</span> Reduced carbohydrate tolerance, fluid retention. <span class="typehead">Body as a Whole:</span>  Leg cramps, edema, intolerance to contact lenses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <b> Carbamazepine,</b> <b>phenytoin,</b> <b>rifampin</b> decrease estrogen levels because they increase its metabolism; may enhance steroid effects of <span class="classification">corticosteroids</span>; may decrease anticoagulant effects of <span class="classification">oral anticoagulants</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 83% absorbed. <span class="typehead">Metabolism:</span> extensively metabolized in liver. <span class="typehead">Elimination:</span> excreted in urine and feces. <span class="typehead">Half-Life:</span> 327 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Check BP on a regular basis in patients with conditions that may be influenced by fluid retention (migraine, cardiac or kidney
            dysfunction, asthma, epilepsy, hypertension).
         </li>
<li>Supplement pyridoxine (vitamin B<sub>6</sub>) in patients on long-term therapy, especially if undernourished; levels are lowered by estrogens.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that risk of blood clot formation is high. Notify physician immediately of positive Homan's sign (calf pain upon
            foot flexion) and the following symptoms of thromboembolic disorders: Tenderness, pain, swelling, and redness in extremity;
            sudden, severe headache or chest pain, slurring of speech; change in vision; sudden shortness of breath. If physician is not
            available, go to the nearest emergency room.
         </li>
<li>Report severe abdominal pain and tenderness, or abdominal mass.</li>
<li>Determine weight under standard conditions 1 or 2 times/wk and report sudden weight gain or other signs of fluid retention.</li>
<li>Notify physician of yellow skin and sclera, pruritus, dark urine, and light-colored stools; history of jaundice in pregnancy
            increases the possibility of estrogen-induced jaundice. Estrogen therapy is usually interrupted pending clinical investigation.
         </li>
<li>Abrupt withdrawal of vitamin C may lead to breakthrough bleeding; high vitamin C intake (e.g., 1 g/d) may increase ethinyl
            estradiol levels.
         </li>
<li>Report symptoms of vaginal candidiasis (thick, white, curd-like secretions and inflamed congested introitus) to permit appropriate
            treatment.
         </li>
<li> 							Note: Estrogen-induced feminization and impotence in male patients are reversible with termination of therapy. 						</li>
<li>Decrease caffeine intake from sources such as tea, coffee, and cola; estrogenic depression of caffeine metabolism may cause
            caffeinism.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>